KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Raw Materials (2009 - 2012)

Merck (MRK) reported Raw Materials of $265.0 million for Q2 2012, down 11.07% year-over-year from $298.0 million in Q3 2011, and down 14.52% on a QoQ basis from $310.0 million in Q1 2012.

Merck (MRK) has 4 years of Raw Materials data on file, last reported at $265.0 million in Q2 2012.

  • Quarterly Raw Materials fell 11.07% year-over-year to $265.0 million in Q2 2012, while the trailing twelve-month figure through Jun 2012 was $265.0 million (down 11.07% YoY) and the FY2011 annual result came in at $297.0 million, down 5.71% from the prior year.
  • Raw Materials eased to $265.0 million in Q2 2012 per MRK's latest filing, from $310.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $5.8 billion in Q3 2011 and bottomed at $265.0 million in Q2 2012.
  • The 4-year median for Raw Materials is $312.5 million (2010), against an average of $1.4 billion.
  • Peak annual rise in Raw Materials reached 1694.0% in 2011, while the deepest fall reached 94.39% in 2011.
  • Tracing MRK's Raw Materials over 4 years: stood at $323.0 million in 2009, then retreated by 2.48% to $315.0 million in 2010, then decreased by 5.71% to $297.0 million in 2011, then decreased by 10.77% to $265.0 million in 2012.
  • Per Business Quant, the three latest MRK Raw Materials figures stand at $265.0 million (Q2 2012), $310.0 million (Q1 2012), and $297.0 million (Q4 2011).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2012 265.00 Mn
Mar 31, 2012 310.00 Mn
Dec 31, 2011 297.00 Mn
Sep 30, 2011 5.80 Bn
Jun 30, 2011 298.00 Mn
Mar 31, 2011 306.00 Mn
Dec 31, 2010 315.00 Mn
Sep 30, 2010 323.30 Mn
Jun 30, 2010 5.31 Bn
Dec 31, 2009 323.00 Mn